Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Denali Therapeutics, a new biotech firm focused on neurodegenerative disease, has launched with an initial investment commitment of $217 million, an amount being called the largest ever for a biotech firm. Denali’s three founders—Ryan Watts, Alexander Schuth, and Marc Tessier-Lavigne—are all former Genentech scientists. Notably, Tessier-Lavigne, now president of Rockefeller University, led R&D at Genentech during the 2000s. Denali says it plans to discover medicines for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other neurodegenerative ailments.
This article has been sent to the following recipient: